Towards an assessment of toxicity in the treatment of ovarian cancer.
Using data from a randomised clinical trial of two platinum drugs at The Royal Marsden Hospital, London, a descriptive model of toxicity has been developed and tested. Toxicity manifests itself in reducing the effectiveness of different body processes; five were selected in this study as being most critical. The model summarises and combines data from these five sites in terms of a clinician's assessment of the associated risk to the patient. It is hoped that the approach will help clarify toxicity information for use in patient management decision-making and in the reporting of clinical trial results.